Company
Melbourne, VIC
Every investor coverage indicates participated in a round Cell Therapies raised.
Companies Cell Therapies acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Cell Therapies. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
AdAlta, an ASX-listed biotech, has completed a $2.5 million placement to progress its CAR-T cancer treatment toward trials, with funds earmarked for US regulatory engagement and a domestic manufacturing transfer via Cell Therapies.
A profile of Chimeric Therapeutics and CEO Rebecca McQualter covering its CAR T cancer therapy, clinical progress, manufacturing partnerships, FDA designations, and path to Phase 2 trials by mid-2026.